Mark Nuttall

Oviva Therapeutics, Inc. is an American company that focuses on improving women's experience of aging through biomedical research, development, and advocacy. Oviva aims to address the unmet need in women's health by expanding funding, research, and clinical development. Currently, the company is developing first-in-class therapeutics to improve ovarian function and extend female healthspan. The company was founded by Daisy Robinton, Patricia K. Donahoe, and David Pepin, with Daisy Robinton serving as the CEO since incorporation.

Vita Therapeutics, Inc. is a biotechnology company based in Baltimore, MD that develops state-of-the-art cellular therapeutics for the treatment of neuromuscular diseases and cancers. The company uses induced pluripotent stem cell (iPSC) technology to engineer specific cell types designed to replace those that are defective in patients. Vita Therapeutics is progressing its co-leading programs VTA-100 and VTA-300 for the treatment of limb-girdle muscular dystrophy (LGMD) and multiple solid tumors with the goal of filing investigational drug applications with the Food and Drug Administration in 2023. The company is developing these proprietary cellular therapies following a dual development strategy beginning with autologous-derived cells before moving to a universal hypoimmunogenic cell line. Vita Therapeutics was founded in 2019 by Douglas Taylor Falk, M.S. and Peter Andersen, Ph.D. Douglas Taylor Falk has been the CEO since 2019.